TRDA · Insider Trading
Entrada Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by TRDA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | MPM BioVentures 2018 GP LLC | 10%+ Owner | Sell | −259,837 | −$1.91M |
| 2026-09-09 | MPM BioVentures 2014, L.P. | 10%+ Owner | Sell | −259,837 | −$1.91M |
| 2026-09-03 | Dipal Doshi | CEO | F | −8,724 | −$62.32K |
| 2026-09-03 | Nathan J Dowden | President & COO | F | −2,528 | −$18.06K |
| 2026-09-03 | Kory James Wentworth | Chief Financial Officer | F | −1,733 | −$12.38K |
| 2026-09-03 | Natarajan Sethuraman | President, Research & Develop. | F | −2,079 | −$14.85K |
| 2026-09-03 | MPM Asset Management Investors BV2014 LLC | 10%+ Owner | Sell | −86,482 | −$617.38K |
| 2026-09-03 | MPM BIOVENTURES 2018, L.P. | 10%+ Owner | Sell | −86,482 | −$617.38K |
| 2026-08-31 | MPM BioVentures 2014 GP LLC | 10%+ Owner | Sell | −86,914 | −$615.78K |
| 2026-08-31 | MPM BioVentures 2018 GP LLC | 10%+ Owner | Sell | −86,914 | −$615.78K |
| 2026-08-26 | MPM BioVentures 2014 GP LLC | 10%+ Owner | Sell | −62,714 | −$461.55K |
| 2026-08-26 | MPM BioVentures 2018 GP LLC | 10%+ Owner | Sell | −62,714 | −$461.55K |
| 2026-08-10 | 5AM Partners V, LLC | 10%+ Owner | Sell | −62,811 | −$431.83K |
| 2026-08-10 | Kush Parmar | Director | Sell | −155,255 | −$1.08M |
| 2026-08-03 | Kush Parmar | Director | Sell | −116,474 | −$807.03K |
| 2026-08-03 | Andrew J. Schwab | 10%+ Owner | Sell | −116,474 | −$807.03K |
| 2026-06-12 | Gina Chapman | Director | A | +19,000 deriv. | — |
| 2026-06-12 | Maha Radhakrishnan | Director | A | +19,000 deriv. | — |
| 2026-06-12 | Bernhardt G Zeiher | Director | A | +19,000 deriv. | — |
| 2026-06-12 | Mary Thistle | Director | A | +19,000 deriv. | — |
| 2026-06-12 | Peter S Kim | Director | A | +19,000 deriv. | — |
| 2026-06-12 | Kush Parmar | Director | A | +19,000 deriv. | — |
| 2026-05-21 | Bernhardt G Zeiher | Director | Buy | +5,000 | +$29.32K |
| 2026-05-04 | Nathan J Dowden | President & COO | MIXED | — | −$203.85K |
| 2026-05-04 | Natarajan Sethuraman | President, Research & Develop. | Sell | −25,907 | −$398.81K |
| 2026-04-02 | Kory James Wentworth | Chief Financial Officer | Sell | −2,500 | −$32.38K |
| 2026-03-11 | Kory James Wentworth | Chief Financial Officer | Sell | −16,477 | −$214.38K |
| 2026-03-11 | Nathan J Dowden | President & COO | Sell | −15,010 | −$195.77K |
| 2026-03-06 | Kory James Wentworth | Chief Financial Officer | Sell | −7,988 | −$97.89K |
| 2026-03-03 | Dipal Doshi | CEO | MIXED | +110,350 | −$340.55K |
| 2026-03-03 | Natarajan Sethuraman | President, Research & Develop. | MIXED | +44,325 | −$134.52K |
| 2026-03-03 | Nathan J Dowden | President & COO | MIXED | +34,539 | −$249.24K |
| 2026-03-03 | Kory James Wentworth | Chief Financial Officer | MIXED | +35,949 | −$101.42K |
| 2025-11-24 | Kory James Wentworth | Chief Financial Officer | Sell | −8,910 | −$88.93K |
| 2025-11-24 | Julian Baker | 10%+ Owner | Buy | +28,867 | +$261.85K |
| 2025-11-18 | Kush Parmar | Director | Sell | −200,000 | −$1.76M |
| 2025-11-18 | 5AM Partners V, LLC | 10%+ Owner | Sell | −200,000 | −$1.76M |
| 2025-11-12 | Baker Bros. Advisors (GP) LLC | 10%+ Owner | Buy | +178,044 | +$1.35M |
| 2025-09-04 | Kory James Wentworth | Chief Financial Officer | F | −1,734 | −$9.42K |
| 2025-09-04 | Nathan J Dowden | President & COO | F | −1,746 | −$9.48K |
| 2025-09-04 | Dipal Doshi | CEO | F | −8,723 | −$47.37K |
| 2025-09-04 | Natarajan Sethuraman | President, Research & Develop. | F | −1,760 | −$9.56K |
| 2025-07-11 | Kush Parmar | Director | Sell | −27,000 | −$202.55K |
| 2025-07-11 | 5AM Partners V, LLC | 10%+ Owner | Sell | −27,000 | −$202.55K |
| 2025-07-01 | 5AM Partners V, LLC | 10%+ Owner | Sell | −125,000 | −$866.63K |
| 2025-07-01 | Kush Parmar | Director | Sell | −125,000 | −$866.63K |
| 2025-06-18 | Peter S Kim | Director | Buy | +50,000 | +$731.68K |
| 2025-06-12 | Kush Parmar | Director | A | +19,000 deriv. | — |
| 2025-06-12 | Peter S Kim | Director | A | +19,000 deriv. | — |
| 2025-06-12 | Mary Thistle | Director | A | +19,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Baker Bros. Advisors (GP) LLC | 10%+ Owner | 4,664,924 | $24.54M |
| Ansbert Gadicke | 10%+ Owner | 4,381,062 | $23.04M |
| MPM BioVentures 2018 LLC | 10%+ Owner | 4,381,062 | $23.04M |
| MPM BioVentures 2014 GP LLC | 10%+ Owner | 4,231,434 | $22.26M |
| MPM BIOVENTURES 2018, L.P. | 10%+ Owner | 4,177,215 | $21.97M |
| MPM Asset Management Investors BV2014 LLC | 10%+ Owner | 4,144,952 | $21.80M |
| MPM BioVentures 2018 GP LLC | 10%+ Owner | 4,106,452 | $21.60M |
| Andrew J. Schwab | 10%+ Owner | 3,941,623 | $20.73M |
| 5AM Partners V, LLC | 10%+ Owner | 3,929,411 | $20.67M |
| MPM BioVentures 2014, L.P. | 10%+ Owner | 3,913,952 | $20.59M |
| Kush Parmar | Director | 1,093,313 | $5.75M |
| Dipal Doshi | CEO | 517,290 | $2.72M |
| Julian Baker | 10%+ Owner | 380,152 | $2.00M |
| Natarajan Sethuraman | President, Research & Develop. | 214,238 | $1.13M |
| Nathan J Dowden | President & COO | 196,060 | $1.03M |
| Kory James Wentworth | Chief Financial Officer | 117,277 | $616.88K |
| Peter S Kim | Director | 92,412 | $486.09K |
| Bernhardt G Zeiher | Director | 5,000 | $26.30K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TRDA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.